Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

Abstract: A beverage container system may include a vessel having an interior volume for containing a beverage and shell having an interior volume for removably coupling vessel therein. The vessel may include an inner wall, an outer sidewall, and a sealed volume between the inner wall and the outer wall. The sealed volume may be at a vacuum pressure. The vessel may be constructed from glass while the shell may be constructed from a durable material such as stainless steel.

Abstract: The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample such as serum.

Abstract: The invention provides a method for isolating medical isotopes, the method having the steps of dissolving titanium nuclear targets to create a solution; contacting the solution with a resin so as to retain the isotopes on the resin and generate an eluent containing titanium; contacting the isotope-containing resin with acid of a first concentration to remove impurities from the resin; and contacting the isotope-containing resin with an acid of a second concentration to remove isotope from the resin.

Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

Abstract: The invention provides a method for isolating scandium, the method having the steps of dissolving titanium nuclear targets to create a solution; contacting the solution with a resin so as to retain scandium on the resin and generate an eluent containing titanium; contacting the scandium-containing resin with acid of a first concentration to remove impurities from the resin; and contacting the scandium-containing resin with an acid of a second concentration to remove scandium from the resin.

Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, a, X1, X2, X3, X4, and X5 are as defined hereinbefore. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3 and a are as defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

Abstract: The present invention relates to covalent conjugates of BET inhibitors and alpha amino acid esters, processes for their preparation, compositions containing them, and to their use in the treatment of various disorders in particular inflammatory and autoimmune diseases, such as rheumatoid arthritis; and cancers.

Abstract: An RF PA and an RF PA protection circuit are disclosed according to one embodiment of the present disclosure. The RF PA includes an RF PA bias circuit and an RF PA transistor element. The RF PA transistor element has a first current terminal and a control terminal. The RF PA protection circuit is coupled between the RF PA bias circuit and the first current terminal. The RF PA protection circuit reduces a current through the first current terminal using the RF PA bias circuit when a magnitude of a voltage at the first current terminal exceeds a protection threshold.

Abstract: The invention provides a method for generating medical isotopes, the method comprising contacting a primary radiation beam with a converter for a time sufficient to produce a secondary beam of gamma particles, and contacting the beam of gamma particles to a target, where the cross section dimension of the beam of gamma particles is similar to the cross section dimension of the target. Both the converter and target are small in diameter and very closely spaced. Also provided is a system for producing medical isotopes, the device comprising a housing having a first upstream end and a second downstream end, a radiotransparent channel (collimator) with a first upstream end and a downstream end, wherein the upstream end is adapted to receive a radiation beam, a target positioned downstream of the downstream end of the channel and coaxially aligned with the channel, wherein the target has a cross section that is similar to the cross section of the channel.

Abstract: The invention provides a method for extracting transition metals, the method comprising supplying a feedstream containing transition metal, mixing the feedstream with nitric acid for a time and at a concentration sufficient to form an aqueous phase containing the transition metal, combining the aqueous phase with organic extractant phase for a time and at a concentration sufficient to cause the transition metal to reside within the organic extractant phase, and combining the transition metal-containing organic extractant phase with an hydroxamic acid-containing aqueous phase at a concentration and for a time sufficient to cause the transition metal to reside in the hydroxamic acid-containing aqueous phase.

Abstract: The present disclosure provides vectors and methods for rapid and efficient integration of DNA at target sites in genomes with high efficiency. The present disclosure also provides methods for creating cell lines to model human diseases, for activating gene expression to correct genetic diseases or even for performing genetic screenings.

Abstract: A packet is identified at a port of a serial data link, and it is determined that the packet is associated with an error. Entry into an error recovery mode is initiated based on the determination that the packet is associated with the error. Entry into the error recovery mode can cause the serial data link to be forced down. In one aspect, forcing the data link down causes all subsequent inbound packets to be dropped and all pending outbound requests and completions to be aborted during the error recovery mode.

Abstract: A packet is identified at a port of a serial data link, and it is determined that the packet is associated with an error. Entry into an error recovery mode is initiated based on the determination that the packet is associated with the error. Entry into the error recovery mode can cause the serial data link to be forced down. In one aspect, forcing the data link down causes all subsequent inbound packets to be dropped and all pending outbound requests and completions to be aborted during the error recovery mode.

Abstract: An apparatus includes a storage device configured to store location information of multiple receivers and auxiliary data associated with a space vehicle. A motion compensation block configured to correct timing of a received signal by a receiver from a space-vehicle transmitter and to generate a motion-compensated signal having corrected timing for motions of the space-vehicle transmitter. The corrected timing is determined based on stored location information of the receiver and the auxiliary data. The frequency correction block is configured to correct a carrier frequency of the motion-compensated signal using information associated with a synch channel of the received signal and to generate a processed signal.

Abstract: The present invention relates to covalent conjugates of BET inhibitors and alpha amino acid esters, processes for their preparation, compositions containing them, and to their use in the treatment of various disorders in particular inflammatory and autoimmune diseases, such as rheumatoid arthritis; and cancers.

Abstract: The invention provides a method for isolating scandium, the method having the steps of dissolving titanium nuclear targets to create a solution; contacting the solution with a resin so as to retain scandium on the resin and generate an eluent containing titanium; contacting the scandium-containing resin with acid of a first concentration to remove impurities from the resin; and contacting the scandium-containing resin with an acid of a second concentration to remove scandium from the resin.

Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

Abstract: An RF PA and an RF PA protection circuit are disclosed according to one embodiment of the present disclosure. The RF PA includes an RF PA bias circuit and an RF PA transistor element. The RF PA transistor element has a first current terminal and a control terminal. The RF PA protection circuit is coupled between the RF PA bias circuit and the first current terminal. The RF PA protection circuit reduces a current through the first current terminal using the RF PA bias circuit when a magnitude of a voltage at the first current terminal exceeds a protection threshold.